To support MIT Technology Review's journalism, please consider becoming a subscriber.
It's a great idea. I think it's time for chip manufacturers to do something for us in biosciences, says a chemist at the University of Michigan and co-founder of aLight Sciences.
There are other companies pursuing chip-based biosensors. Dynamic Biosensors has chips with light-based sensors. Merriman says that Roswell's manufacturing approach produces precise sensors that are flexible enough to be mass produced with modern chip-making techniques.
The center of Roswell's circuits is a chain of amino acids that is connected to the rest of the chip, just as a regular metallic wire would be. A molecule is attached to the other end of the wire. When this molecule interacts with its intended target, its electrical conductivity changes. The chip records the change, and software extracts the interaction details.
Roswell biotechnOLOGIES.
Roswell starts with a Silicon chip studded with pre-made nanomaterials and uses electric voltage to pull the molecule out of the solution and onto the chip. In the past, similar processes took hours or even days, but this part of the assembly process only takes 10 seconds.
Roswell's approach could bring back some of the hopes of 20 years ago. It seemed like the small size of molecules could help make circuit components tinier. George Church, a Harvard geneticist, says that a chipmaker could self- assemble circuits, adding molecules under highly controlled conditions and letting them assemble into desired structures all by themselves.
There was a rapid growth of the molecular electronics field in the late 1990s. It seemed like the perfect time to make the predictions about how Silicon was going to hit a brick wall. Engineers kept pushing ahead. He says that Silicon just kept getting better. Nine out of 10 researchers dropped out of the University of California, Irvine, where Philip Collins is a physicist.
Roswell is targeting an application that is ill-suited to the new chip. Collins says that Molecules are special because they can be so complex.
Roswell and other on-chip technology makers have shared a vision of biosensors that would allow people to check in on their vitamins and infections with less hassle than it takes to check their heart rate on a watch. In Roswell, thousands of biosensors could detect different interactions at the same time, and the chips would be disposable.
Walter of the University of Michigan notes that Roswell's device can accommodate more than 10,000 biosensors on one chip, but having hundreds of thousands, or millions, more would push the device toward a more useful function.
Paul Mola is Roswell's CEO and Barry Merriman is the co-founder.
Church, Merriman, and other company leaders have been in the market before. The Roswell team's experience and expertise has not made the company's financing journey easier. Mola says he expected venture capital to pour in after the company's paper in January. Roswell has raised more than $60 million so far, but it had to reduce its workforce by nearly half in February.
Mola is frustrated by the lack of investment in the company.
Mola says that part of the problem is with the track record of the biotech industry. He says that Black founders don't have that.
Mola says that Roswell is on track to release a commercial device by the end of the year. The next funding series is about to start. It is also introducing a service that may draw in customers before it is possible to sell chips to them directly: scientists will now be able to send samples to Roswell and have its biosensors work on them in house.
It is nice to be able to see something happen and to say that it did work, we just took longer than we thought.
Karmela Padavic-Callaghan is a freelance journalist based in Brooklyn, New York.
All Rights Reserved © 2024
